Subscription payment model for HCV drugs will reduce costs in Australia

Australia's "subscription" model for HCV drugs is more cost effective than standard payment models, according to a paper published Feb. 14 in the New England Journal of Medicine.

In 2015, Australia negotiated a five-year unlimited supply of HCV drugs from Gilead Sciences Inc. (NASDAQ:GILD), AbbVie Inc. (NYSE:ABBV), Bristol-Myers Squibb Co. (NYSE:BMY) and Merck & Co. Inc. (NYSE:MRK) for approximately A$1 billion ($766 million)...